ET Intelligence Group: Corona Remedies, a pharma company, plans to raise Rs 655.4 crore through an offer for sale. The promoter group’s stake will fall to 69% after the IPO from 72.5%. The company focuses on the specialist doctors, driving revenue growth faster than the Indian pharmaceutical market (IPM). Specialists accounted for 75.8% of the … Read more
The US economy also witnessed substantial issues in its pharma market. In addition to these, manufacturing & exporting countries around the world saw heightened raw material price inflation followed by supply chain disruption. All these affected the margins of the companies deeply. Synopsis Indian pharmaceutical market flattened after the pandemic led to a massive upsurge … Read more
NEW DELHI:Drug firm Lupin remains bullish over its US business with over 158 applications for generic products pending with the US drug regulator for approval, as per the company’s annual report for 2019-20. Sharing information with company’s shareholders, Lupin MD Nilesh Gupta and CEO Vinita Gupta said the company’s US business stabilised last fiscal and … Read more